12/22/2022, Newark // Future Market Insights, Inc. //

[179 Pages Report] Rising burden of various types of cancers such as ovarian, breast, prostate, and pancreatic cancer is anticipated to generate significant demand for PARP inhibitors. According to the Global Cancer Observatory (GLOBOCAN), countries such as China, the U.S., India, and Japan, collectively diagnose over 120,000 new cases of ovarian cancer each year.

For in-depth insights, Download a PDF Brochure – 

The post PARP Inhibitors Market is estimated to top US$ 5.51 Bn by 2022, growing at an impressive CAGR of 11.2% from 2022-2026 | FMI appeared first on Future Market Insights.

Source: Future Market Insights, Inc.

Release ID: 474294

Original Source of the original story >> PARP Inhibitors Market is estimated to top US$ 5.51 Bn by 2022, growing at an impressive CAGR of 11.2% from 2022-2026 | FMI

This content is published on behalf of the above source. Please contact them directly for any concern related to the above. 

This press release may contain forward-looking statements. Forward-looking statements describe future expectations, plans, results, or strategies (including product offerings, regulatory plans and business plans) and may change without notice. You are cautioned that such statements are subject to a multitude of risks and uncertainties that could cause future circumstances, events, or results to differ materially from those projected in the forward-looking statements, including the risks that actual results may differ materially from those projected in the forward-looking statements.